iA Global Asset Management Inc. Sells 21,080 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

iA Global Asset Management Inc. lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 91.5% during the 4th quarter, HoldingsChannel reports. The firm owned 1,950 shares of the medical research company’s stock after selling 21,080 shares during the period. iA Global Asset Management Inc.’s holdings in Charles River Laboratories International were worth $360,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Versant Capital Management Inc grew its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Tortoise Investment Management LLC grew its position in Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock worth $49,000 after acquiring an additional 115 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in Charles River Laboratories International in the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in Charles River Laboratories International in the third quarter worth $59,000. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $167.29 on Friday. The company has a market cap of $8.55 billion, a price-to-earnings ratio of 1,115.26, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a 50-day moving average price of $166.11 and a 200-day moving average price of $183.71. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $273.57.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the firm earned $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% on a year-over-year basis. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CRL shares. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a research report on Monday, March 3rd. UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. Finally, Robert W. Baird cut their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $189.77.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).